GlassScriptPhysician profile
Pooja Bardhan
NPI 1962601344
$2,989.98
in general payments reported to CMS, 2019-2025
46 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $14.65 · 2021: $70.95 · 2023: $418 · 2024: $1,092 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.66 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Daiichi Sankyo INC. | $196.16 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $191.94 | 2020-2025 | |
| Genzyme Corporation | $182.27 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $119.91 | 2019-2025 | |
| Janssen Biotech, INC. | $116.50 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Glaxosmithkline, LLC. | $96.22 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $93.07 | 2023-2025 | Venclexta, Tecentriq, Polivy |
| Exelixis INC. | $87.02 | 2019-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $84.30 | 2024 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $83.75 | 2024-2025 | Verzenio, Jaypirca |
| Beigene USA, INC. | $74.80 | 2023-2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $74.59 | 2019-2021 | |
| Gilead Sciences, INC. | $72.46 | 2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $72.32 | 2019-2024 | Fruzaqla |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $72.02 | 2024-2025 | Libtayo |
| Stemline Therapeutics INC. | $68.27 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $67.08 | 2023-2025 | |
| Abbvie INC. | $65.18 | 2024-2025 | |
| Tersera Therapeutics LLC | $62.98 | 2024-2025 | Xermelo |
| Bayer Healthcare Pharmaceuticals INC. | $49.08 | 2023 | |
| Array Biopharma INC | $46.99 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Seagen INC. | $44.44 | 2023 | Padcev |
| Acrotech Biopharma INC. | $44.03 | 2024 | Beleodaq |
| G1 Therapeutics, INC. | $39.19 | 2023 | Cosela |
| Mirati Therapeutics, INC. | $38.09 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $38.01 | 2025 | Ayvakit |
| Coherus Oncology, INC. | $37.08 | 2021-2024 | |
| Emd Serono, INC. | $35.26 | 2025 | |
| Immunocore Limited | $35.24 | 2025 | Kimmtrak |
| Celgene Corporation | $32.96 | 2025 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $32.52 | 2024 | Ultomiris |
| Pharmaessentia USA Corporation | $30.78 | 2024 | Besremi |
| Kite Pharma, INC. | $27.95 | 2025 | Yescarta |
| Avyxa Pharma, LLC | $26.72 | 2025 | |
| Dendreon Pharmaceuticals LLC | $25.27 | 2024 | Provenge |
| Eisai INC. | $24.71 | 2024 | |
| Fennec Pharmaceuticals, INC. | $24.63 | 2024 | Pedmark |
| Shield Therapeutics INC | $23.87 | 2024 | |
| Octapharma USA, INC. | $21.94 | 2023 | Octagam Immune Globulin (Human) |
| Legend Biotech USA INC. | $21.88 | 2025 | Carvykti |
| Novocure INC. | $19.52 | 2024 | Optune Lua (Novottf-200t) |
| E.R. Squibb & Sons, L.L.C. | $18.34 | 2024 | |
| Tesaro, INC. | $16.01 | 2019 | |
| Beone Medicines USA, INC. | $15.39 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Bardhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.